Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Endothelial dysfunction (ED) has been suggested as a possible causal link between
postprandial hyperglycemia and cardiovascular events in patients with type 2 diabetes. Recent
trials demonstrated a reduction of cardiovascular events by treatment with the alpha
glucosidase inhibitor acarbose - a drug which mainly reduces postprandial glucose excursions.
We were interested whether patients with newly diagnosed type 2 diabetes showed postprandial
ED and if so whether acarbose was able to improve this condition.